|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic and Translational Investigations |
1 Divisions of Hematology and Hematopoietic Cell Transplantation and Neurosciences and Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
2 Neurosurgical Oncology Laboratory, Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School, Department of Neurosurgery, University Hospital Hamburg-Eppendorf
3 Neurosurgical Oncology Laboratory, Department of Neurosurgery, Brigham and Women's Hospital and Children's Hospital, Harvard Medical School
4 Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, and Departments of Surgery and Neurosurgery, Tufts-New England Medical Center and Tufts University School of Medicine
 |
Abstract |
|---|
Brain metastases are an increasingly frequent and serious clinical problem for cancer patients, especially those with advanced melanoma. Given the extensive tropism of neural stem/progenitor cells (NSPCs) for pathological areas in the central nervous system, we expanded investigations to determine whether NSPCs could also target multiple sites of brain metastases in a syngeneic experimental melanoma model. Using cytosine deaminase-expressing NSPCs (CD-NSPCs) and systemic 5-fluorocytosine (5-FC) pro-drug administration, we explored their potential as a cell-based targeted drug delivery system to disseminated brain metastases. Our results indicate a strong tropism of NSPCs for intracerebral melanoma metastases. Furthermore, in our therapeutic paradigm, animals with established melanoma brain metastasis received intracranial implantation of CD-NSPCs followed by systemic 5-FC treatment, resulting in a significant (71%) reduction in tumor burden. These data provide proof of principle for the use of NSPCs for targeted delivery of therapeutic gene products to melanoma brain metastases.
Key Words: brain metastases, cytosine deaminase, gene therapy, melanoma, neural progenitor cells, neural stem cells, tumor targeting
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Ganta, D. Chiyo, R. Ayuzawa, R. Rachakatla, M. Pyle, G. Andrews, M. Weiss, M. Tamura, and D. Troyer Rat Umbilical Cord Stem Cells Completely Abolish Rat Mammary Carcinomas with No Evidence of Metastasis or Recurrence 100 Days Post-Tumor Cell Inoculation Cancer Res., March 1, 2009; 69(5): 1815 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhao, J. Najbauer, E. Garcia, M. Z. Metz, M. Gutova, C. A. Glackin, S. U. Kim, and K. S. Aboody Neural Stem Cell Tropism to Glioma: Critical Role of Tumor Hypoxia Mol. Cancer Res., December 1, 2008; 6(12): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kucerova, V. Altanerova, M. Matuskova, S. Tyciakova, and C. Altaner Adipose Tissue-Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy Cancer Res., July 1, 2007; 67(13): 6304 - 6313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Palmieri, A. F. Chambers, B. Felding-Habermann, S. Huang, and P. S. Steeg The Biology of Metastasis to a Sanctuary Site Clin. Cancer Res., March 15, 2007; 13(6): 1656 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. K. Danks, K. J. Yoon, R. A. Bush, J. S. Remack, M. Wierdl, L. Tsurkan, S. U. Kim, E. Garcia, M. Z. Metz, J. Najbauer, et al. Tumor-Targeted Enzyme/Prodrug Therapy Mediates Long-term Disease-Free Survival of Mice Bearing Disseminated Neuroblastoma Cancer Res., January 1, 2007; 67(1): 22 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-K. Kim, S. U. Kim, I. H. Park, J. H. Bang, K. S. Aboody, K.-C. Wang, B.-K. Cho, M. Kim, L. G. Menon, P. M. Black, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res., September 15, 2006; 12(18): 5550 - 5556. [Abstract] [Full Text] [PDF]
|
|
|
|
